Ocular Adverse Effects Linked to Antibody-Drug Conjugates in Cancer Treatment: An In-Depth Analysis

1

Ocular toxicity from antibody-drug conjugates (ADCs) can impair visual function and significantly affect quality of life and treatment adherence.
2

ADC-induced ocular adverse events have led to treatment discontinuation in over 50% of patients during clinical trials.
3

The cytotoxic payload of ADCs, particularly microtubule inhibitors and DNA-damaging agents, is a major contributor to ocular toxicity.
4

The FDA has issued boxed warnings for specific ADCs due to their associated ocular adverse effects.
5

A comprehensive understanding of ocular toxicity mechanisms may help reduce its incidence and improve clinical outcomes in ADC therapy.

Frontiers In Immunology

1